NSRX.US Nasus Pharma Ltd.

Healthcare Pharmaceuticals USA Stocks
2.87 USD
Close of Nov 15, 2026
1.98 9.50
Market cap
USD 33.6M
P/E
-
P/B
3.06x
ROE
-162.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NSRX.US undervalued?

Graham number

The Graham number of Nasus Pharma Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nasus Pharma Ltd. fundamental analysis

No fundamental analysis for Nasus Pharma Ltd. yet.

Nasus Pharma Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nasus Pharma Ltd.

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdos…

Full company profile